WANY
ALNY icon

Wealthspire Advisors (New York)’s Alnylam Pharmaceuticals ALNY Stock Holding History

Wealthspire Advisors (New York)’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-20
Closed -$9.26K – 1099
2025
Q3 		$9.26K Buy
+20
New +$8.14K ﹤0.01% 2056

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Wealthspire Advisors (New York)'s ALNY Position: Q4 2025 in Review

Wealthspire Advisors (New York) sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2025, closing a stake of 20 shares — an estimated $9.26K sold.

Wealthspire Advisors (New York) first reported a position in ALNY in Q3 2025 and held it in 1 quarter. The position peaked at $9.26K in Q3 2025. 850 funds tracked by Wall St. Rank hold ALNY as of Q4 2025.

  • Wealthspire Advisors (New York) reported no remaining Alnylam Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Wealthspire Advisors (New York) sold 20 Alnylam Pharmaceuticals shares in Q4 2025, an estimated $9.26K.
  • Wealthspire Advisors (New York) first reported a position in Alnylam Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • Wealthspire Advisors (New York)'s Alnylam Pharmaceuticals position peaked at $9.26K in Q3 2025.
  • 850 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2025.

Based on Wealthspire Advisors (New York)'s 13F filing for Q4 2025, filed 13 Feb 2026.